Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 08, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 800,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,249.08 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.07% of total voting rights).
- Shares in Issue: 5,229,942,574 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 800,000 repurchased shares. Consequently, the total number of shares in issue remains 5,229,942,574, while the Treasury holding stands at 474,194,158 shares. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the standard disclosure that the announcement does not constitute an offer to purchase securities. The transaction was conducted in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,229,942,574) for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the Treasury share count (474,194,158) and its impact on total voting rights (9.07%).
- Note that this filing is a notification of a specific share buyback event and does not contain quarterly or annual financial performance data.